DXCM — DEXCOM INC
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1093557 ·
Last close
$78.19
Market Cap
$30.17B
52W High
$78.82
52W Low
$56.72
ADV30
6,785,451
Next earnings
2026-07-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,191,900,000 | 750,300,000 | 255,300,000 | 199,500,000 | 6,633,300,000 | 1,118,200,000 | 3,676,400,000 |
| Dec 2025 | 1,259,600,000 | 792,700,000 | 323,000,000 | 267,300,000 | 6,339,900,000 | 917,700,000 | 3,593,900,000 |
| Sep 2025 | 1,209,300,000 | 731,400,000 | 242,500,000 | 283,800,000 | 7,500,000,000 | 1,835,700,000 | 4,773,900,000 |
| Jun 2025 | 1,157,100,000 | 688,800,000 | 212,600,000 | 179,800,000 | 7,327,000,000 | 1,159,000,000 | 4,753,900,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$1,782,500,000
Investing CF
$137,300,000
Financing CF
$-1,723,900,000
CapEx
$-353,100,000
Dividends Paid
—
Buybacks
$-1,062,800,000
EPS Diluted TTM
$2.34
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$2,633,400,000
Inventory
$693,600,000
Receivables
$1,105,200,000
ST Investments
$1,297,000,000
EBIT TTM
$1,220,300,000
Pretax Income TTM
$1,203,600,000
Interest Exp TTM
$16,700,000
Analysts
24
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,817,900,032
EBITDA
$1,292,300,032
Free Cash Flow
$1,056,637,504
Enterprise Value
$28,535,187,456
Total Cash
$2,415,200,000
Total Debt
$1,384,800,000
Shares Out
385,872,977
Trailing EPS
$2.33
Book Value
$7.66
ROE
35.6%
ROA
9.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,662,000,000 | 911,800,000 | 836,300,000 | 6,339,900,000 | 3,593,900,000 | — | 1,440,700,000 |
| Dec 2024 | 4,033,000,000 | 600,000,000 | 576,200,000 | 6,484,500,000 | 4,381,900,000 | — | 989,500,000 |
| Dec 2023 | 3,622,300,000 | 597,700,000 | 541,500,000 | 6,264,500,000 | 4,195,900,000 | — | 748,500,000 |
| Dec 2022 | 2,909,800,000 | 391,200,000 | 341,200,000 | 5,391,700,000 | 3,259,900,000 | — | 669,500,000 |
TTM Snapshot
Revenues TTM
$3,389,000,000
NetIncome TTM
$443,800,000
OpCashFlow TTM
$0
Assets (Latest)
$6,484,500,000
Forward EPS
$3.08
Max Pain — expiry 2026-06-18
max pain strike: $105.00 · spot: $78.19 · call oi: 1,854 · put oi: 169Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GEHC | GE HealthCare Technologies Inc. | $30.03B | $66.01 | — |
| MDLN | Medline Inc. | $30.45B | $36.01 | — |
| FSNUF | Fresenius SE & Co. KGaA | $30.61B | $54.35 | — |
| RMD | RESMED INC | $28.57B | $196.94 | — |
| PHG | KONINKLIJKE PHILIPS NV | $25.76B | $26.50 | — |
News headlines (Yahoo Finance, 1h cache)
DexCom Reports Positive CONNECT Data for Non-Insulin Diabetes
2026-06-08 17:29 · Yahoo
Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
2026-06-06 18:45 · Yahoo
Assessing DexCom (DXCM) Valuation After Recent Share Price Momentum
2026-06-06 18:07 · Yahoo
Is DexCom Stock Underperforming the Dow?
2026-06-05 10:46 · Yahoo
Dexcom buys Nutrisense; Insulet rolls out patch pump update
2026-06-05 10:25 · Yahoo
Here's Why You Should Retain DexCom Stock in Your Portfolio
2026-06-04 18:08 · Yahoo
DexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026?
2026-06-04 16:10 · Yahoo
Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
2026-06-04 13:00 · Yahoo
Tandem Diabetes Valuation: Is 1.1x Sales a Buy?
2026-06-03 15:25 · Yahoo
Did FDA-App Recalls and Activist Pressure Just Rewire Dexcom’s (DXCM) Software-Driven Investment Narrative?
2026-06-03 01:07 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.